Gilead Sciences | GILD - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 7.61B 2.04B 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amgen USD 2.08B 570M 2026-03
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 8.85B 583.8M 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 751.51M 407.91M 2026-06
J&J USD 8.66B 839M 2026-06
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR 837M 1.17B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
United Therapeutics USD 372.7M 54.4M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06